Financial health
- Operating income covered interest expense -68.1× in the latest year.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
ALLR Financials Allarity Therapeutics, Inc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $320000 | -$11M | 0.0% | -3939.1% | -114.3% | -61.5% | -$15M | — | $15M |
| 2024 | $0 | -$25M | — | — | -207.6% | -108.2% | -$18M | — | $20M |
| 2023 | — | -$12M | — | — | 432.6% | -100.3% | -$13M | $3M | $166000 |
| 2022 | — | -$16M | — | — | 14210.6% | -110.4% | -$17M | $3M | $2M |
| 2021 | — | -$27M | — | — | -146.8% | -53.7% | — | — | — |
| 2020 | — | -$7M | — | — | -27.1% | -19.8% | -$7M | — | $298000 |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $0 | -$3M | — | — | -96.3% | -10.6% | -$3M | — | $17M |
| Mar '26 | $25000 | -$3M | 0.0% | -10752.0% | -39.7% | -7.9% | -$5M | — | $20M |
| Dec '25 | — | -$3M | — | — | -34.3% | -18.5% | — | — | $15M |
| Sep '25 | — | -$3M | — | — | -23.4% | -13.5% | — | — | $17M |
| Jun '25 | $0 | -$2M | — | — | -19.1% | -10.9% | -$5M | — | $18M |
| Mar '25 | $0 | -$3M | — | — | -14.6% | -9.2% | -$3M | — | $25M |
| Dec '24 | — | -$7M | — | — | -63.1% | -32.9% | — | — | $20M |
| Sep '24 | — | -$12M | — | — | -89.4% | -56.9% | — | — | — |
| Jun '24 | — | -$2M | — | — | -8.2% | -5.3% | — | — | $19M |
| Mar '24 | — | -$4M | — | — | 59.4% | -32.1% | — | — | $312000 |
| Dec '23 | — | -$2M | — | — | 62.6% | -14.5% | — | $3M | $166000 |
| Sep '23 | — | -$4M | — | — | 131.6% | -32.1% | — | $3M | $1M |
| Jun '23 | — | -$2M | — | — | 329.2% | -17.7% | — | — | $420000 |
| Mar '23 | — | -$3M | — | — | 108.1% | -26.4% | — | — | $295000 |
| Dec '22 | — | -$3M | — | — | 2511.5% | -19.5% | — | $3M | $2M |
| Sep '22 | — | -$5M | — | — | -348.1% | -27.8% | — | — | $4M |
| Jun '22 | — | -$5M | — | — | -64.1% | -22.0% | — | — | $8M |
| Mar '22 | — | -$3M | — | — | -20.9% | -9.8% | — | — | — |
| Dec '21 | — | -$17M | — | — | -92.6% | -33.9% | — | — | — |
| Sep '21 | — | -$1M | — | — | -4.6% | -3.7% | — | — | $6M |
Valuation over time
How the market has priced ALLR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 53.9× (Dec '25) to 55.2× (Nov '26).
P/S
Frequently asked questions
Is ALLR growing its revenue and profit?
See the revenue and net-income charts above for Allarity Therapeutics, Inc.'s multi-year trend.
How much debt does ALLR have?
As of FY2025, Allarity Therapeutics, Inc. reported — of total debt against $15M of cash; operating income covered interest expense -68.1×.
What is ALLR's profit margin?
In FY2025, gross margin was —, operating margin -3939.1%, and net margin -3509.7%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.